These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38875370)

  • 1. Efficacy evaluation and exploratory analysis of influencing factors of Banxia Houpu Decoction in the treatment of refractory gastroesophageal reflux disease.
    Song S; Zhang Y; Zhang J; Jiang Y; Gong A
    Medicine (Baltimore); 2024 Jun; 103(24):e38045. PubMed ID: 38875370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Banxia-houpu decoction restores glucose intolerance in CUMS rats through improvement of insulin signaling and suppression of NLRP3 inflammasome activation in liver and brain.
    Jia KK; Zheng YJ; Zhang YX; Liu JH; Jiao RQ; Pan Y; Kong LD
    J Ethnopharmacol; 2017 Sep; 209():219-229. PubMed ID: 28782622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
    Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
    J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical observations on 46 cases of globus hystericus treated with modified Banxia Houpu decoction.
    Bo P; Chen QM; Zhu HH; Zhang XD; Xu HR; Zhang Y; Cao YJ
    J Tradit Chin Med; 2010 Jun; 30(2):103-7. PubMed ID: 20653165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
    Sakata Y; Tominaga K; Kato M; Takeda H; Shimoyama Y; Takeuchi T; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Fujimoto K; Kusano M; Arakawa T;
    BMC Gastroenterol; 2014 Jul; 14():116. PubMed ID: 24990161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chinese medicine Banxia-houpu decoction regulates c-fos expression in the brain regions in chronic mild stress model in rats.
    Zhang W; Li J; Zhu J; Shi Z; Wang Y; Kong L
    Phytother Res; 2004 Mar; 18(3):200-3. PubMed ID: 15103665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
    Tominaga K; Iwakiri R; Fujimoto K; Fujiwara Y; Tanaka M; Shimoyama Y; Umegaki E; Higuchi K; Kusano M; Arakawa T;
    J Gastroenterol; 2012 Mar; 47(3):284-92. PubMed ID: 22081052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant evaluation of polysaccharides from a Chinese herbal medicine Banxia-houpu decoction.
    Guo Y; Kong L; Wang Y; Huang Z
    Phytother Res; 2004 Mar; 18(3):204-7. PubMed ID: 15103666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment for gastroesophageal reflux disease: Traditional Chinese medicine Xiaochaihu decoction.
    Xu LY; Yu BY; Cen LS
    World J Gastroenterol; 2022 Mar; 28(11):1184-1186. PubMed ID: 35431502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of reflux laryngopharyngitis with modified banxia xiexin tang (Pinellia decoction for draining the heart)--a report of 40 cases.
    Xu G
    J Tradit Chin Med; 2006 Jun; 26(2):127-31. PubMed ID: 16817279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and biochemical studies on chronic mild stress models in rats treated with a Chinese traditional prescription Banxia-houpu decoction.
    Li JM; Kong LD; Wang YM; Cheng CH; Zhang WY; Tan WZ
    Life Sci; 2003 Nov; 74(1):55-73. PubMed ID: 14575813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.
    Tominaga K; Kato M; Takeda H; Shimoyama Y; Umegaki E; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Kusano M; Fujimoto K; Arakawa T;
    J Gastroenterol; 2014 Oct; 49(10):1392-405. PubMed ID: 24535455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of Yukgunja-tang combined with a proton pump inhibitor for refractory gastroesophageal reflux disease: study protocol for randomized, double-blind, double-dummy clinical trial.
    Ha NY; Kim JW; Kim J
    BMC Complement Med Ther; 2023 Dec; 23(1):444. PubMed ID: 38062418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
    Fujiwara Y; Habu Y; Ashida K; Kusano M; Higuchi K; Arakawa T
    Digestion; 2013; 88(3):145-52. PubMed ID: 24008338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment method for refractory gastroesophageal reflux disease (GERD): C-BLART (clip band ligation anti-reflux therapy)-a short-term study.
    Liu S; Chai N; Zhai Y; Zou J; Feng X; Li Z; Li L; Zhang X; Wang X; Wang S; Linghu EQ
    Surg Endosc; 2020 Oct; 34(10):4516-4524. PubMed ID: 31728750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
    Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
    World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.